104 related articles for article (PubMed ID: 8675981)
21. [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
Nagayoshi J; Higashi T; Maruyama Y
Hinyokika Kiyo; 1999 Aug; 45(8):543-6. PubMed ID: 10500960
[TBL] [Abstract][Full Text] [Related]
22. Flutamide photosensitivity--residual vitiliginous lesions.
Vilaplana J; Romaguera C; Azón A; Lecha M
Contact Dermatitis; 1998 Feb; 38(2):68-70. PubMed ID: 9506217
[TBL] [Abstract][Full Text] [Related]
23. [Regarding a case of prostate cancer in a young male].
Guerra del Barrio E; Escribano Sevillano D; Sánchez Gómez FJ; Ojer Tsakiridu D
Rev Clin Esp; 2004 Apr; 204(4):236-7. PubMed ID: 15104939
[No Abstract] [Full Text] [Related]
24. Flutamide-induced liver toxicity including fatal hepatic necrosis.
Crownover RL; Holland J; Chen A; Krieg R; Young BK; Roach M; Fu KK
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):911-5. PubMed ID: 8598370
[TBL] [Abstract][Full Text] [Related]
25. [Total androgen blockade for prostate cancer].
Kagebayashi Y; Ozono S; Takashima K; Yoshikawa M; Hayashi Y; Kaneko Y; Maruyama Y; Hirao Y; Okajima E
Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
[TBL] [Abstract][Full Text] [Related]
26. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
27. [Liver failure caused by flutamide].
Guzmán Martínez-Valls PL; Ferrero Doria R; Morga Egea JP; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Gil Franco J; Fontana Compiano LO
Actas Urol Esp; 1997 Mar; 21(3):278-82. PubMed ID: 9324896
[TBL] [Abstract][Full Text] [Related]
28. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
29. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
30. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
Wilson KS; Ludgate CM; Wilson AG; Alexander AS
Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
[TBL] [Abstract][Full Text] [Related]
31. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
32. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
Tanvetyanon T; Choudhury AM
J Urol; 2004 Apr; 171(4):1627. PubMed ID: 15017238
[No Abstract] [Full Text] [Related]
33. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
34. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
Rosenthal SA; Linstadt DE; Leibenhaut MH; Andras EJ; Brooks CP; Stickney DR; Chang GC; Wolkov HB; Gilbert RM
Radiology; 1996 May; 199(2):451-5. PubMed ID: 8668793
[TBL] [Abstract][Full Text] [Related]
35. [A case of prostate cancer associated with osteolytic bone metastases].
Migita T; Maeda K; Ogata N
Hinyokika Kiyo; 1999 May; 45(5):371-4. PubMed ID: 10410324
[TBL] [Abstract][Full Text] [Related]
36. [A case of prostate cancer treated with combined androgen-blockade].
Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
[TBL] [Abstract][Full Text] [Related]
37. Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms.
Pontiroli L; Sartori M; Pittau S; Morelli S; Boldorini R; Albano E
Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):310-4. PubMed ID: 9759603
[TBL] [Abstract][Full Text] [Related]
38. Anemia in patients on combined androgen block therapy for prostate cancer.
Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
[TBL] [Abstract][Full Text] [Related]
39. [Fatal hepatic failure following hepatitis caused by flutamide: a case report].
Okaneya T; Murata Y; Kinebuchi Y
Nihon Hinyokika Gakkai Zasshi; 1999 May; 90(5):590-3. PubMed ID: 10386060
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen for flutamide/finasteride-induced gynecomastia.
Staiman VR; Lowe FC
Urology; 1997 Dec; 50(6):929-33. PubMed ID: 9426725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
